Business Standard

Tuesday, December 24, 2024 | 12:36 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Pharma giant GSK buys US cancer drugmaker Tesaro for hefty $5.1 bln

Tesaro boosts GSK's pharma portfolio at high price $75/ share; cash from Horlicks sale to help fund pharma investment

This microbot can capture cells like a tiny Pac-Man, may help probe cancer
Premium

An electron micrograph of a prostatic cancer cell. Photo: Reuters

Reuters London
GlaxoSmithKline has agreed to buy US cancer specialist Tesaro for $5.1 billion, marking a major biotech investment by Chief Executive Emma Walmsley as she seeks to rebuild the group's pharmaceuticals business.

GSK has lagged rivals in recent years in producing multibillion-dollar blockbusters and it largely sat out a spate of dealmaking by rival drugmakers under previous CEO Andrew Witty. That is a situation Walmsley now wants to change.

Britain's biggest drugmaker is paying $75 a share for the business, an 110 percent premium to the 30-day average price. It is also taking on Tesaro's debt. News of the lofty valuation

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in